The Summer School on Pharmaceutical Analysis (SSPA) addresses the most advanced analytical methodologies involved in the development of new drugs and in drug manufacturing. The ultimate goal of a drug discovery program is to generate a candidate drug compound that, besides being active and selective in vitro on the isolated target, is safe and efficacious in humans. In order to develop such a compound, many criteria including affinity, activity, selectivity, physico-chemical properties, and pharmacokinetics must be optimized. The definition of these criteria involves the availability and knowledge of appropriate analytical methodologies.
SSPA2021 will focus on Analytical methods to achieve efficiency in the hit-to-lead process and will feature the following main sessions:
Quality assurance in the hit-to-lead process
Hit-to-lead: potency and selectivity
Bioavailability and toxicology
Analytical aspects in preformulation
There will also be a special session dedicated to case reports discussed by R&D managers of companies operating in the field of drug discovery. Lectures will be delivered by recognized experts from the academic and industrial sectors. A list of confirmed lecturers is available at the section “meet the speakers”. The School welcomes PhD students and scientists from academia and industry. To guarantee partecipants' safety, the 2021 edition of the School will be delivered as fully virtual meeting in lieu of the originally scheduled face-to-face meeting. The virtual SSPA2021 will offer the same rich lecture program and will be easily accessible for partecipants from all over the World.
We are looking forward to welcoming you at the 2021 virtual edition of the School.
Chair of SSPA
Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna
22 - 24 Sept 2021
12 Drug Discovery Professionals
The ultimate goal of a drug discovery program is to generate a candidate drug compound that, besides being active and selective in vitro on the isolated target, is safe and efficacious in humans. In order to develop such a compound, many criteria including affinity, activity, selectivity, physico-chemical properties, and pharmacokinetics must be optimized. The definition of these criteria involves the availability and knowledge of appropriate bio-analytical methodologies.
He is full professor in medicinal chemistry at the University of Milan. So far he has held several positions within international organizations and from 2013 to 2019 he was the director of the Summer School in Pharmaceutical analysis and since 2017 he is the Director of the Ph.D School in Pharmaceutical Sciences at the University of Milan. His main research interest is devoted to the development and application of high resolution mass spectrometric techniques in drug discovery and development. He is the author of more than 180 papers with an H index of 49 and he has been an invited speaker at several international congresses and seminars.
He holds a PhD degree in Chemistry and has a long experience in medicinal chemistry and drug discovery. He started his career in the industry working at the discovery of new drugs for Alzheimer’s disease. After moving to the Oncology area, he was appointed as project leader of discovery projects aiming at the search for antagonists of the αvβ3 integrin, tyrosine kinase inhibitors, and inhibitors of arginine methyltransferases. At IIT, he has continued his research activity focusing on the identification of new drugs for the treatment of inflammatory diseases and cystic fibrosis.
He studied biophysics at the University of Trento and trained at the Carnegie-Mellon University, The Scripps Research Institute, and the University of Lausanne. He joined Sandoz (now Novartis) in 1989 as lab head prior to his position in 1999 as head of the biomolecular NMR group at Pharmacia & Upjohn and then group leader at the Italian Institute of Technology. Afterwards he worked as NMR senior expert and associate professor at the University of Neuchâtel. His research interests are in NMR spectroscopy, from methodology development to its applications in chemistry and biology, fragment-based drug discovery and enzymology.
Master's Degree, Chemistry and Pharmaceutical Technology from Padua University. She has more than 20 years of experience in the Pharmaceutical Industry with a strong background in drug product development in particular for early phase projects. She started in GlaxoSmithKline as product development scientist focusing in biopharmaceutical aspects and assessment of oral dosage form starting from in vitro tools to predict in vivo performance. She moved in Aptuit in 2010 with main role of pharmaceutical development representative in international project teams, working mainly in multi-disciplinary integrated project teams as client interface. She is actually responsible for Pharmaceutical Development department involved in developing formulation from preclinical dosing to clinical manufacturing phase.
He got his Industrial Chemistry Degree in 1986. From 1998 he worked for SmithKline Beecham as Medicinal Chemist and Team Leader of the Delta Opioid Agonists Programme. In 1999 he was appointed Assistant Director Medicinal Chemistry Italy. In 2001 he co-founded NiKem Research a CRO for integrated medicinal chemistry services and was Director of DMPK and Developability Sciences. Presently he is COO and co-founder of Aphad, a CRO for pharmacokinetics and analytical services. He is author of more than 40 articles on international journals and 17 patents. He held lectures at several Italian Universities (Siena, Pavia, Genova, Pavia, Pisa and Milano).
He is Associate Professor at the University of Perugia (Italy). After studying organic synthesis, in 2005 he obtained his PhD in medicinal chemistry with Prof. Roberto Pellicciari. Antimo Gioiello has led several academic and industrial collaborations and his work experience spans various stages of early drug discovery in the area of liver and metabolic diseases. His main research interests include steroid chemistry, the discovery of NCEs for nuclear receptors, and the development of automated flow platforms for lead discovery and process chemistry. Antimo Gioiello is a co-founder of TES Pharma and member of the Board of Directors at the University of Perugia.
He got his Master’s Degree in Chemistry at the University of Ferrara and spent more than 19 years working in quantitative bioanalysis, regulatory guidelines and new technologies implementation. During his career he worked for GSK, APTUIT, Menarini and he is actually a Senior Research Leader for the Evotec Discovery DMPK department. He had also experience in outsourcing activities, due diligence support and is also an expert in lab automation, method development and problem solving. He is also author of publications in the bioanalytical and data integrity field.
Scientist at Accelera S.r.l. with a 20-year experience in bioanalysis. She grew up professionally thanks to her work in industries, such as Pharmacia, where she conducted her thesis in Medicinal Chemistry (CTF), Cell Therapeutics Inc. and Nerviano Medical Sciences. She has been involved in several bioanalytical activities concerning the quantitation of small molecules by LC-MS/MS, from early discovery to regulated development stages of drug research. Actually she has the role of study director. Her responsibilities span from the coordination of multisite projects to the planning, conducting and supervising of regulated preclinical and clinical studies.
She has a degree in Pharmaceutical Chemistry and Technology and a Master in Experimental Pharmacology (University of Milan). Since January 2007, she is Director of the Discovery Services Department at AXXAM, with the responsibility of the units of: Cell Biology, Biochemistry, Screening Technologies, Electrophysiology, High Content Screening, Molecular Biology, Cell Factory and iPSC. She is program director for many of the collaborations in place with national and international companies, as well as principal investigator for projects granted by the Italian government, the European Commission, and international organisms.
She met the Mass Spectrometry during her thesis in Organic Chemistry at the University of Pavia and never stopped working in that field since then. She had the opportunity to work in several pharmaceutical companies in Analytical Department group and as a support to research group always using Mass Spectrometry. She started with Bracco in 1996 using an ion trap to characterise synthetic compounds, move then to Zambon in 1998 to coordinate different activities in both analytical research and development but spent about 10 years in the company that was Pharmacia &Upjohn at the begininning and now is Nerviano Medical Sciences. When in P&U she met the HRMS used mainly to support the impurity profile among many other activities. In 2004 she decided to change her view and move to work in Waters as High-Resolution Mass Spectrometry (HRMS) specialist supporting customers in different application areas (from Met ID, to ADC characterization through small molecule structural ID).
He graduated in Pharmaceutical Technology and Chemistry in 1984 at Pisa University. His professional activity has been exerted in the fields of Medicinal and Analytical Chemistry. Presently, he is involved in the Menarini R&D Projects, mainly in structural elucidation of new drugs and their impurities, metabolites, biomolecules and natural products, through the use of advanced chromatographic and spectroscopic techniques, particularly GC-MS and LC-MS. Besides this, he exerts didactic activity in chromatography and mass spectrometry for Master and PhD courses. He is author of publications in pharmaceutical analysis, bioanalysis, medicinal chemistry and metabolite identification.
Degree in Pharmaceutical Chemistry (CTF) and Certified as Pharmacist at Università degli Studi di Padova. She has more than 15 years of experience in the Pharmaceutical Industry performing different roles in different regulated environments. She started in GMP quality assurance in GlaxoSmithKline Manufacturing as a microbiological specialist and then as a filling expert acquiring knowledge of GMP regulations applied to the production of cephalosporin for injection in a sterile environment. After two years she moved to the Bioanalytical department of GlaxoSmithKline R&D where she worked in a GLP environment, moving then to GLP/GCP QA. She now has the role of Manager of GLP/GCP quality assurance in Aptuit, an Evotec Company, responsible for all Quality Assurance GLP and GCP activities. Her responsibilities range from assuring Test Facility Management of compliance with GLP/GCP principles to provide regulatory support to the Business operations, to manage the validation of computerized systems, host Client and Regulatory inspections, collect and trend quality metrics.
Please fill in the on-line registration form here and send a copy of the bank transfert by email to the SSPA2021 Secretariat at firstname.lastname@example.org. Your registration will be confirmed only upon reception of the Proof of Payment.
NOT SCI/EFMC member
Registration policy and fees All registrations will be accepted until September 20th, 2021. After this date, no registration will be accepted.
GDPR The personal information we receive from participants will also be required after the School for statistical purposes and for the dispatch of information on relevant symposia/school in the future. If you do not wish your personal data to be published or distributed, please inform us when you register for the summer school.
Confirmation An e-mail confirming your registration will be sent to you upon reception of a pdf proof of bank trasnfer.
Cancellation must be submitted in writing to the SSPA 2021 Secretariat (email@example.com). The policy regarding refund of the registration fee is as follows: for cancellations received before September 13th, 2021 there will not be a cancellation charge (bank fee shall be deducted). After the September 13th, 2021 no refund will be made.
Payment All payments should be made in Euro by bank transfer to:
Account holder: Società Chimica Italiana-SSPA
Bank address: DEUTSCHE BANK MILANO C 463, VIALE GIUSTINIANO 1
Iban Code: IT50N0310401603000000821734
Swift Code: DEUT IT M1463
Remittance have to be free of any bank charges to the organizers.
Proof of Payment must be submitted by e-mail (firstname.lastname@example.org) at the time of registration. Please ensure that the name and company/University of each delegate is printed clearly to ensure that the payment will be correctly registered. The payment receipt, together with the attendance certificate, will be provided at the registration when registering.
Thanks to the support of Italfarmaco, the Divisione di Chimica Farmaceutica of the Società Chimica Italiana (Italian Chemical Society) grants 3 fellowships for the participation to SSPA2021. Fellowships, covering the registration fee, are reserved to young members of the Divisione di Chimica Farmaceutica with no permanent position at their institution (PhD students, graduated fellows and post-doctoral fellows, volunteers or young researchers from other public research bodies), born after 30 April 1986.
A Committee will carry out the selection on the basis of the candidate scientific CV and research project. More details are available here (in Italian).
Applicants are invited to send the CV, a motivation letter and the abstract of the research project, by e-mail, stating in the subject box “Candidatura Bando Borse di Studio SSPA 2021”, within May 15th, 2021 (NEW DEADLINE).
Italian and foreign Ph.D. students in the end phase of their Ph.D. project are kindly invited to orally present their work (20 minutes including discussion). Abstracts will be evaluated by the scientific committee prior acceptance. In the case the number of candidate presentations exceed the number that can be accommodated in the program, a selection will be made on the basis of novelty, pertinence, and clarity. Abstracts for Ph.D. oral presentations must be submitted before June 30, 2021, according to the template given here.